Cargando…
L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies
Adaptive clinical trials are underway to determine the efficacy of potential therapies for COVID-19, with flexibility to include emerging therapies if there is sufficient preclinical evidence for their potential utility. In silico screening of connectivity maps, which link gene expression profiles t...
Autor principal: | Sendama, Wezi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719280/ https://www.ncbi.nlm.nih.gov/pubmed/33312454 http://dx.doi.org/10.1016/j.csbj.2020.11.054 |
Ejemplares similares
-
The effect of ageing on the resolution of inflammation
por: Sendama, Wezi
Publicado: (2020) -
Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining
por: Liu, Tsang-Pai, et al.
Publicado: (2018) -
Traumatic chylothorax: A case report and review
por: Sendama, Wezi, et al.
Publicado: (2015) -
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020) -
Clinical Trials of Repurposed Antivirals for SARS-CoV-2
por: Martinez, Miguel Angel
Publicado: (2020)